Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

Share Price is delayed by 15 minutes
Get Live Data
7.40    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.20 (2.74%)
Market Cap: £3.24m
FDBK Live PriceLast checked at - London Stock Exchange

Intraday Feedback Share Chart

Director Appointment

29 Nov 2021 13:36

RNS Number : 9144T
Feedback PLC
29 November 2021
 

Feedback plc

 

Appointment of Anesh Patel as Chief Financial Officer and Company Secretary 

 

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist clinical communication company, is pleased to announce that further to previous announcements, Anesh Patel has been appointed to the board of directors as Chief Financial Officer and Company Secretary with immediate effect.

 

Anesh Patel was appointed as Chief Financial Officer of Feedback's wholly owned subsidiary, Feedback Medical Limited, in May 2021 as part of a succession planning programme following Lindsay Melvin's (Chief Financial Officer and Company Secretary of Feedback) decision to retire from the board of Feedback during H2 2021. Anesh has worked alongside Lindsay over the past months to ensure a smooth and orderly transition.

 

Anesh joined Feedback Medical Limited from hVIVO Limited, a subsidiary of AIM-listed Open Orphan plc and a rapidly growing, industry-leading, clinical services provider to pharma, biotech and government organisations where most recently he was finance & corporate projects director. Prior to hVIVO, he spent seven years in investment banking where he specialised in corporate finance advisory services, at leading banks including Société Générale and Standard Bank. Anesh started his professional career with Ernst & Young in 2004 where he qualified as a chartered accountant, initially working within the audit & assurance division before transferring to the transaction support team for private equity clients. He graduated from University College London (UCL) and holds an M.Sci. (Hons) degree in Mathematics with Economics.

 

Rory Shaw, Chairman of Feedback, commented: "We welcome Anesh to the Board of Feedback. He joined the team earlier this year and has already proven the value he brings through his contribution to the successful £11.2 million fundraise recently announced. His broad financial and commercial experience provides a good balance to the medical and technical expertise we have across the Board, creating a strong team to take the Company forward. I would also like to take this opportunity to thank Lindsay for his work guiding the Company through its formative years, and for enabling a smooth handover to ensure Feedback continues on this trajectory of growth. We believe that Feedback is set for a bright and exciting future ahead."

 

Aneshkumar (Anesh) Ishwarbhai Patel (aged 40) does not currently hold any directorships and has no previous directorships (within 5 years). Anesh Patel has confirmed that there is no further information to be disclosed pursuant to paragraph (g) of Schedule 2 of the AIM Rules.

 

Enquiries:

 

Feedback plc

Tom Oakley, CEO

Anesh Patel, CFO

+44 (0)1954 718072

IR@fbk.com

Panmure Gordon (UK) Limited (NOMAD and Broker)

Emma Earl/Freddy Crossley (Corporate Finance)

Rupert Dearden (Corporate Broking)

+44 (0)20 7886 2500

Walbrook PR Ltd

Tel: 020 7933 8780 or feedbackplc@walbrookpr.com

Paul McManus/Nick Rome/Nicholas Johnson

07980 541 893 or 07748 325 236 or 07884 664 686

 

Notes to Editors

 

Feedback plc (AIM: FDBK) is a pioneer of regulated clinical communication products. Its core product, Bleepa, is a revolutionary medical imaging communications app, providing an easy-to-use, high quality tool to enable remote and secure communications between front-line clinicians and teams. Importantly, it is the only CE marked medical imaging communications platform on the NHSx clinical communications tools framework. Bleepa has unparalleled functionality for everyday practice and can be accessed from any internet-connected device, enabling control of patient cases when on the go.

 

Its highly scalable Software as a Service ("SaaS") based revenue model will provide increasing levels of visibility as the Company grows its customer base. With a growing distribution base and technology in place, the focus is on leveraging key relationships in order to drive sales both in the UK and internationally to all forms of care providers. As a fully certified medical device, Bleepa aims to disrupt the medical imaging communications market and, importantly, increase the accuracy and speed of clinical review.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOADKCBBNBDDFDB
Date   Source Headline
22nd Apr 20262:10 pmRNSGrant of Options and PDMR dealing
20th Apr 20267:00 amRNSNHS Progress and Business Update
17th Feb 202610:43 amRNSCorrection: Half-year Report
17th Feb 20267:00 amRNSHalf-year Report
2nd Feb 20267:00 amRNSNotice of Results & Retail Investor Presentation
5th Jan 20264:13 pmRNSHolding(s) in Company
23rd Dec 20253:44 pmRNSHolding(s) in Company
23rd Dec 20253:44 pmRNSHolding(s) in Company
23rd Dec 20253:33 pmRNSDirector/PDMR Shareholding
23rd Dec 20253:33 pmRNSDirector/PDMR Shareholding
18th Dec 20257:00 amRNSTrading Update
20th Oct 20257:00 amRNSDirectorate Change
13th Oct 20254:04 pmRNSResult of AGM
18th Sep 20251:07 pmRNSNotice of AGM
17th Sep 20257:00 amRNSFinal Results
8th Sep 20257:00 amRNSNotice of Results & Retail Investor Presentation
10th Jul 20257:00 amRNSGrant of Options and PDMR dealing
12th Jun 20257:00 amRNS-RNeighbourhood Health Service Simulation
7th May 202510:44 amRNSHolding(s) in Company
6th May 20251:01 pmRNSHolding(s) in Company
28th Apr 20257:00 amRNSTrading Update
25th Feb 20257:00 amRNSHalf-year Report
11th Feb 20257:00 amRNSNotice of Results & Investor Presentation
14th Jan 20257:00 amRNSSurrender and grant of options and PDMR dealings
18th Dec 20243:07 pmRNSHolding(s) in Company
18th Dec 20247:00 amRNSHalf Year Trading Update
9th Dec 202410:56 amRNSHolding(s) in Company
9th Dec 202410:48 amRNSHolding(s) in Company
4th Dec 20247:00 amRNSHolding(s) in Company
3rd Dec 202412:33 pmRNSHolding(s) in Company
3rd Dec 202412:18 pmRNSHolding(s) in Company
2nd Dec 202411:53 amRNSHolding(s) in Company
2nd Dec 202411:46 amRNSHolding(s) in Company
2nd Dec 20247:00 amRNSDirector/PDMR Shareholding
29th Nov 20243:36 pmRNSHolding(s) in Company
29th Nov 20243:33 pmRNSHolding(s) in Company
28th Nov 20242:35 pmRNSResult of AGM & Commercial Update
6th Nov 20247:00 amRNSResult of WRAP Retail Offer
4th Nov 20243:46 pmRNSSuccessful Fundraising upscaled to c. £5.57m
4th Nov 20247:02 amRNSWRAP Retail Offer for up to £1 million
4th Nov 20247:01 amRNSProposed Fundraise & Share Capital Reorganisation
4th Nov 20247:00 amRNSFinal Results
16th Oct 20247:00 amRNSElective Recovery Fund funding mechanism
19th Sep 20247:00 amRNSCollaboration Agreement
2nd Sep 20247:00 amRNSFurther funding to extend NHS Trust pathways
10th Jul 20247:00 amRNSVertex In Healthcare Collaboration
1st Jul 20247:00 amRNSCDC Contract Awarded by Queen Victoria Hospital
28th Jun 20247:00 amRNSChange of Name of Nominated Adviser and Broker
22nd May 20247:00 amRNSTrading Update
25th Mar 20247:00 amRNSNew tuberculosis partnership in India

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.